Ignite Creation Date:
2025-12-25 @ 3:45 AM
Ignite Modification Date:
2026-01-12 @ 1:37 PM
Study NCT ID:
NCT04792502
Status:
RECRUITING
Last Update Posted:
2025-03-21
First Post:
2021-03-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Sponsor:
Organization: